Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 96

Results For "Europe"

997 News Found

EpiEndo Pharma secures  EUR 20 Million Series A funding for Macrolide
Biotech | August 18, 2021

EpiEndo Pharma secures EUR 20 Million Series A funding for Macrolide

The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication


Novartis secures new approval in China for Cosentyx in pediatric psoriasis
Drug Approval | August 18, 2021

Novartis secures new approval in China for Cosentyx in pediatric psoriasis

Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch


India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad
interviews | August 17, 2021

India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad

India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers


Suven Life Sciences announces Phase 3 clinical trial of Masupirdine
Biotech | August 17, 2021

Suven Life Sciences announces Phase 3 clinical trial of Masupirdine

This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024


Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19
Biotech | August 17, 2021

Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19

The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.


Lupin receives tentative U.S. FDA approval for Brivaracetam tablets
Drug Approval | August 17, 2021

Lupin receives tentative U.S. FDA approval for Brivaracetam tablets

Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older


Indian pharma’s vaccine opportunity at US $ 10-11 billion
Biotech | August 17, 2021

Indian pharma’s vaccine opportunity at US $ 10-11 billion

Domestic market and developing countries will need doses of Indian vaccines


Antiviral face mask capable of inactivating COVID19
News | August 16, 2021

Antiviral face mask capable of inactivating COVID19

The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)


Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
Drug Approval | August 12, 2021

Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness

A treatment to prevent extreme symptoms and cut hospitalisation


Global Healthcare Supply Chain Management market to reach US $ 3.6 billion by 2026
Supply Chain | August 11, 2021

Global Healthcare Supply Chain Management market to reach US $ 3.6 billion by 2026

A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report